Evidence map›Paper›PMID 41729401›Full record

ArticleClinical journal of gastroenterology2026

A case of IgA vasculitis developing in a patient with Crohn's disease treated with adalimumab.

Harujiro Yamamoto, Yusuke Wakisaka, Yasuhiro Aoki, Atsuto Kayashima, Takahiro Matsunaga, Kazuyo Watanabe, Seiichiro Fukuhara

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Harujiro YamamotoDepartment of Gastroenterology and Hepatology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Yusuke WakisakaDepartment of Gastroenterology and Hepatology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan. wacky0119@hotmail.co.jp.ORCID http://orcid.org/0009-0005-0113-5243
Yasuhiro AokiDepartment of Gastroenterology and Hepatology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Atsuto KayashimaDepartment of Gastroenterology and Hepatology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Takahiro MatsunagaDepartment of Gastroenterology and Hepatology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Kazuyo WatanabeDepartment of Gastroenterology and Hepatology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.
Seiichiro FukuharaDepartment of Gastroenterology and Hepatology, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate a suggestive case of IgA vasculitis that developed following acute tonsillitis in a patient with Crohn's disease treated with adalimumab. IgA vasculitis and Crohn's disease can both cause abdominal pain, joint pain, and erythema, making an early diagnosis difficult. When they occur together, it can be challenging to determine which is the primary condition. Due to similar symptoms, a careful assessment and thorough understanding of each disease's characteristics are essential for an accurate diagnosis and proper management. In this case, the overlapping of immunological events due to anti-tumor necrosis factor-ɑ (TNF-ɑ) agents and infection, in addition to pre-existing immune abnormalities, may be contributing factors to the development of IgA vasculitis. Based on this experience, we suggest that patients with inflammatory bowel disease receiving anti-TNF-ɑ agents should be monitored not only for the relapse of their underlying disease but also for the development of IgA vasculitis following tonsillitis.

Indexed as

AdalimumabAnti-Inflammatory AgentsCrohn DiseaseImmunoglobulin ATonsillitisVasculitisHumansTumor Necrosis Factor-alphaAdalimumabAnti-Inflammatory AgentsImmunoglobulin ATumor Necrosis Factor-alphaAdalimumabAnti-TNF-ɑ agentsCrohn’s diseaseIgA vasculitis

Identifiers

PMID41729401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.